Welcome to the Boeckh Group
The long-term goal of the Boeckh Research Program is to prevent infectious disease in immunocompromised hosts and reduce the severity of infections that do occur. We focus on herpes viruses (primarily cytomegalovirus and human herpes virus 6), respiratory viruses, and the genetics of susceptibility to infection.
Clinical Trials
The following trials are presently being conducted by Dr. Boeckh’s Group.
- The GRAIL Study - CMV Prevention in Patients with Respiratory Failure
- The Safety and Efficacy of Therapeutic CMV vaccine ASP0113
- The Safety and Efficacy of Brincidofovir (CMX001) for Treatment of Adenovirus Infection
- Effects of DAS181 for Treatment of Parainfluenza Infection in Immunocompromised Subjects
- Effects of DAS181 for Treatment of Parainfluenza Pneumonia in Immunocompromised Subjects
- Effects of GS-5806 for Treatment of RSV Infection of the Upper Respiratory Tract in Hematopoietic Transplant Recipients
- Effects of GS-5806 for Treatment of RSV Infection of the Lower Respiratory Tract in Hematopoietic Transplant Recipients
- Observational Long-Term Follow-Up of Patients Who Received CMX001 in Selected Clinical Studies
Boeckh lab
Boeckh Group clinical team
